Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048308 · ClinicalTrials.gov registry record · Phase 3
Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass
A Phase 3 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
NCT00048308 is a Phase 3 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 3,000 participants.
The verdict
NCT00048308, a Phase 3 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out if the study drug (pexelizumab), which blocks complement release, can reduce such side effects and be taken safely.
Interventions
- DRUG pexelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Start Date | 2002-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00048308
The ClinicalTrials.gov registry entry for NCT00048308 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which pexelizumab is the first listed.
NCT00048308 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00048308 about?
NCT00048308 is a clinical study titled "Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass". During a heart bypass procedure, a substance called "complement" is released by the body. This complement causes inflammation, which can lead to side effects such as chest pain, heart attacks, heart failure, or impairment of memory, language and motor skills. The purpose of this study is to find out...
What is the current status of trial NCT00048308?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants. The study started on 2002-01.
What interventions are being tested in trial NCT00048308?
The interventions under investigation include: pexelizumab (DRUG).
Who is sponsoring clinical trial NCT00048308?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.